| Title |
Cannabis for dyskinesia in Parkinson disease
|
|---|---|
| Published in |
Neurology, October 2004
|
| DOI | 10.1212/01.wnl.0000140288.48796.8e |
| Pubmed ID | |
| Authors |
C B. Carroll, P G. Bain, L Teare, X Liu, C Joint, C Wroath, S G. Parkin, P Fox, D Wright, J Hobart, J P. Zajicek |
| Abstract |
The long-term treatment of Parkinson disease (PD) may be complicated by the development of levodopa-induced dyskinesia. Clinical and animal model data support the view that modulation of cannabinoid function may exert an antidyskinetic effect. The authors conducted a randomized, double-blind, placebo-controlled crossover trial to examine the hypothesis that cannabis may have a beneficial effect on dyskinesia in PD. |
X Demographics
The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 13% |
| France | 2 | 13% |
| Côte d'Ivoire | 1 | 6% |
| Australia | 1 | 6% |
| Japan | 1 | 6% |
| India | 1 | 6% |
| China | 1 | 6% |
| North Macedonia | 1 | 6% |
| United Kingdom | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 5 | 31% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 14 | 88% |
| Practitioners (doctors, other healthcare professionals) | 1 | 6% |
| Science communicators (journalists, bloggers, editors) | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 276 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | <1% |
| United States | 2 | <1% |
| Spain | 1 | <1% |
| Unknown | 271 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 37 | 13% |
| Student > Master | 35 | 13% |
| Researcher | 31 | 11% |
| Other | 25 | 9% |
| Student > Doctoral Student | 21 | 8% |
| Other | 52 | 19% |
| Unknown | 75 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 62 | 22% |
| Neuroscience | 29 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 21 | 8% |
| Agricultural and Biological Sciences | 20 | 7% |
| Psychology | 17 | 6% |
| Other | 42 | 15% |
| Unknown | 85 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 39. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 November 2023.
All research outputs
#1,056,206
of 25,459,177 outputs
Outputs from Neurology
#1,818
of 21,035 outputs
Outputs of similar age
#1,136
of 76,062 outputs
Outputs of similar age from Neurology
#4
of 105 outputs
Altmetric has tracked 25,459,177 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 21,035 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.7. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 76,062 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 105 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.